Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc. has successfully completed the first synthetic production of psilocin at the GMP manufacturing facility of its recently acquired GMP Drug Inc.
"Awakened's successful first synthetic production of psilocin at the GMP Drug Inc. facilities is a major accomplishment for Core One, and it lays the groundwork for the large-scale production of psychedelic compounds at a GMP certified facility. As Core One looks to become a major supplier of psychedelic compounds, it is important that we demonstrate the company's ability to execute at each stage of our strategic process. This achievement brings us one step closer to our long-term goal of supplying the medical community with affordable, API grade, psychedelic compounds," stated Joel Shacker CEO of the company.
The successful synthesis of psilocin advances previous work conducted by Awakened, where its team of scientist witnessed success in the ability to produce a precursor that can be efficiently converted into psilocin, with further conversion into commercially viable psilocybin. The confirmation of Awakened's synthetic production methods is also extremely important for the future developments of the company, as it lays the path upon which additional research can be conducted. As such, Awakened will look to replicate methods used in the successful synthetic production of psilocin and subsequent conversion to psilocybin, for future production of dimethyltryptamine and its intermediates, and other psychedelic prodrugs and compounds.
The research and resulting production have been led by CEO of Awakened, Dr. Tony Durst, who is also an emeritus professor at the University of Ottawa, and a renowned specialist in medicinal and natural product chemistry. Dr. Durst's previous successes are many and include the awarding of 14 successful patents, of which he was co-inventor.
Photo by Louis Reed on Unsplash
Related News
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
Core One實驗室公司(OTCQB：CLABF)(CSE：COOL)(法蘭克福：LD6)(WKN：A3CSSU)宣佈其全資子公司，覺醒的生物科學公司。有成功地完成了首個裸鼠毒素的合成生產在其最近收購的GMP製造工廠GMP藥品公司。
Core One的一項重大成就是在GMP製藥公司的設施中成功地首次成功合成了裸鼠毒素，並為在GMP認證的設施中大規模生產迷幻化合物奠定了基礎。隨著Core One希望成為迷幻化合物的主要供應商，我們必須證明該公司在我們戰略過程的每個階段都有執行的能力。這一成就使我們離向醫學界提供負擔得起的、原料藥級別的迷幻化合物的長期目標又近了一步喬爾·謝克公司的首席執行官。
裸蓋菇素的成功合成推進了之前由覺醒公司進行的工作，該公司的科學家團隊見證了成功地生產出一種可以有效轉化為裸蓋菇素的前體，並進一步轉化為商業上可行的裸蓋菇素。確認覺醒的合成生產方法對公司未來的發展也是極其重要的，因為它為進一步的研究奠定了基礎。因此，覺醒公司將尋求複製成功合成裸蓋菇素並隨後轉化為裸蓋菇素的方法，用於未來生產二甲基色胺及其中間體，以及其他迷幻前藥和化合物。
這項研究和由此產生的成果一直由覺醒的首席執行官領導，Tony·德斯特博士他也是渥太華大學的榮譽退休教授，也是一位著名的藥物和天然產品化學專家。德斯特博士之前的成功很多，包括授予14項成功的專利，他是這些專利的共同發明人。
路易·裡德在Unspash上拍攝的照片
相關新聞
全球：治療晚期癌症的迷幻試驗，阿爾茨海默氏症開始
